Global production capacity of seasonal and pandemic influenza vaccines in 2019

Sparrow, Erin; Wood, James G.; Chadwick, Christopher; Newall, Anthony T.; Torvaldsen, Siranda; Moen, Ann; Torelli, Guido

doi:10.1016/j.vaccine.2020.12.018

Cited by 79 publications

(83 citation statements)

References 35 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Continuous flow ultracentrifugation is a method used to produce >80% of the annual global influenza vaccine inventory which is approximately 1.5 billion doses (33), Continuous flow ultracentrifugation is thus an ideal and an established method for purification at large scale. To assess the potential yields of our production process, we produced a batch of mCuMV TT -RBM in a 2litre fermenter and purified the resultant VLPs by continuous flow ultracentrifugation (Fig 7A).…”

Section: Efficient Upscaling Of Mcumv Tt -Vlps Vaccine Candidatementioning

confidence: 99%

A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2

Mohsen

Baļķe

Zinkhan

et al. 2021

Preprint

View full text Add to dashboard Cite

SARS-CoV-2 caused one of the most devastating pandemics in the recent history of mankind. Due to various countermeasures, including lock-downs, wearing masks and increased hygiene, the virus has been controlled in some parts of the world. More recently, the availability of vaccines, based on RNA or Adenoviruses, have greatly added to our ability to keep the virus at bay, again in some parts of the world only. While available vaccines are effective, it would be desirable to also have more classical vaccines at hand for the future. Key feature of vaccines for long-term control of SARS-CoV-2 would be inexpensive production at large scale, ability to make multiple booster injections and long-term stability at +4 C. Here we describe such a vaccine candidate, consisting of the SARS-CoV-2 receptor binding motif grafted genetically onto the surface of the immunologically optimized cucumber mosaic virus, called CuMV -RBM. Using bacterial fermenter production and continuous flow centrifugation, the productivity of the production process is estimated to be >2.5 million doses per 1000 liter fermenter run and the vaccine candidate is stable for at least 14 months at 4°C. We further demonstrate that the candidate vaccine is highly immunogenic in mice and rabbits and induces more high avidity antibodies compared to convalescent human sera and antibodies induced are more cross-reactive to mutant RBDs for variants of concern (VoC). Furthermore, antibody responses are neutralizing and long-lived. This, the here presented VLP-based vaccine may be a good candidate for use as conventional vaccine in the long-term.

show abstract

Section: Efficient Upscaling Of Mcumv Tt -Vlps Vaccine Candidatementioning

confidence: 99%

A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2

Mohsen

Baļķe

Zinkhan

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…This, however, could be the reason that seasonal influenza vaccines have not greatly evolved over the last 40 years, despite their low efficacy for certain sectors of the population, including young children. On the other hand, we must acknowledge the effort made by vaccine manufactures to develop the infrastructure for the production of the current seasonal influenza vaccine, which has the potential to produce 1.48 billion seasonal and 8.31 billion pandemic doses globally [ 120 ]. Nonetheless, considering the nature of the influenza virus and the increasing demands to consider individual needs, more options for different influenza vaccines should be available.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Selecting and Using the Appropriate Influenza Vaccine for Each Individual

Sekiya

Ohno

Nomura

et al. 2021

Viruses

View full text Add to dashboard Cite

Despite seasonal influenza vaccines having been routinely used for many decades, influenza A virus continues to pose a global threat to humans, causing high morbidity and mortality each year. The effectiveness of the vaccine is largely dependent on how well matched the vaccine strains are with the circulating influenza virus strains. Furthermore, low vaccine efficacy in naïve populations such as young children, or in the elderly, who possess weakened immune systems, indicates that influenza vaccines need to be more personalized to provide broader community protection. Advances in both vaccine technologies and our understanding of influenza virus infection and immunity have led to the design of a variety of alternate vaccine strategies to extend population protection against influenza, some of which are now in use. In this review, we summarize the progress in the field of influenza vaccines, including the advantages and disadvantages of different strategies, and discuss future prospects. We also highlight some of the challenges to be faced in the ongoing effort to control influenza through vaccination.

show abstract

“…In light of the current global influenza vaccine production capacity, it is unlikely that there would be sufficient vaccine available in the first 12 months of an influenza pandemic to meet global needs. Production capacities to provide a monovalent inactivated influenza vaccine at 15 μg HA per dose, as currently used in seasonal influenza vaccines, are estimated at 4 to 6 billion doses [ 11 , 12 ]. A study from the 2009 swine flu pandemic showed that eight months after the first detection of the virus, less than 500 million doses of monovalent vaccine of any sort were produced [ 13 ], which would have been woefully insufficient in the case of a pandemic of higher severity.…”

Section: Pandemic Influenza Vaccine Developmentmentioning

confidence: 99%

Better Pandemic Influenza Preparedness through Adjuvant Technology Transfer: Challenges and Lessons Learned

Lemoine

Nidom²,

Ventura

et al. 2021

Vaccines

View full text Add to dashboard Cite

Adequate global vaccine coverage during an influenza pandemic is essential to mitigate morbidity, mortality, and economic impact. Vaccine development and production needs to be sufficient to meet a vast global demand, requiring international cooperation and local vaccine production capacity, especially in resource-constrained countries. The use of adjuvants is one approach to augment the number of available vaccine doses and to overcome potential vaccine shortages. Appropriately selected adjuvant technologies can decrease the amount of vaccine antigen required per dose, may broaden or lengthen the conferred protection against disease, and may even allow protective single-dose vaccination. Here we describe a technology transfer collaboration between Switzerland and Indonesia that led to the establishment of a vaccine formulation platform in Surabaya which involved the transfer of equipment and expertise to enable research and development of adjuvanted vaccine formulations and delivery systems. This new Indonesian capability aims to facilitate local and regional access to know-how relating to adjuvanted vaccine formulations, thus promoting their application to local vaccine developers. In this review, we aim to share the “lessons learned” from this project to both support and inspire future scientific collaborations of a similar nature.

show abstract

Global production capacity of seasonal and pandemic influenza vaccines in 2019

Cited by 79 publications

References 35 publications

A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2

A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2

Selecting and Using the Appropriate Influenza Vaccine for Each Individual

Better Pandemic Influenza Preparedness through Adjuvant Technology Transfer: Challenges and Lessons Learned

Contact Info

Product

Resources

About